| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Eribulin |
| Brand | Halaven® |
| Indication | For the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. |
| Assessment Process | |
| Rapid review commissioned | 09/02/2011 |
| Rapid review completed | 09/03/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 26/09/2012 |
| NCPE assessment completed | 07/12/2012 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
The NCPE believe that, at the submitted price, eribulin (Halaven®) is not cost effective for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.
December 2014
The HSE has approved reimbursement following confidential price negotiations.
